IL299747A - Transgenic antibody against IGE and its application - Google Patents

Transgenic antibody against IGE and its application

Info

Publication number
IL299747A
IL299747A IL299747A IL29974723A IL299747A IL 299747 A IL299747 A IL 299747A IL 299747 A IL299747 A IL 299747A IL 29974723 A IL29974723 A IL 29974723A IL 299747 A IL299747 A IL 299747A
Authority
IL
Israel
Prior art keywords
amino acid
antigen
binding protein
acid mutations
positions
Prior art date
Application number
IL299747A
Other languages
English (en)
Hebrew (he)
Original Assignee
Shanghai Jemincare Pharmaceuticals Co Ltd
Jiangxi Jemincare Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jemincare Pharmaceuticals Co Ltd, Jiangxi Jemincare Group Co Ltd filed Critical Shanghai Jemincare Pharmaceuticals Co Ltd
Publication of IL299747A publication Critical patent/IL299747A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL299747A 2020-07-10 2021-07-09 Transgenic antibody against IGE and its application IL299747A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010663029 2020-07-10
CN202110750959 2021-07-01
PCT/CN2021/105620 WO2022007965A1 (zh) 2020-07-10 2021-07-09 一种抗IgE的工程化抗体及其应用

Publications (1)

Publication Number Publication Date
IL299747A true IL299747A (en) 2023-03-01

Family

ID=79552269

Family Applications (1)

Application Number Title Priority Date Filing Date
IL299747A IL299747A (en) 2020-07-10 2021-07-09 Transgenic antibody against IGE and its application

Country Status (11)

Country Link
US (1) US20230250191A1 (cg-RX-API-DMAC7.html)
EP (1) EP4180454A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023541217A (cg-RX-API-DMAC7.html)
KR (1) KR20230042030A (cg-RX-API-DMAC7.html)
CN (1) CN116018352A (cg-RX-API-DMAC7.html)
AU (1) AU2021306786A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023000400A2 (cg-RX-API-DMAC7.html)
CA (1) CA3185192A1 (cg-RX-API-DMAC7.html)
IL (1) IL299747A (cg-RX-API-DMAC7.html)
TW (1) TWI896700B (cg-RX-API-DMAC7.html)
WO (1) WO2022007965A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL318098A (en) 2022-07-01 2025-02-01 Alk Abell? As IGE-FCER pushers
CN116143932B (zh) * 2022-12-07 2025-02-11 南开大学 一种针对IgE的抗体或其抗原结合片段以及Fc变体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1260521B1 (en) 1991-08-14 2007-11-21 Genentech Inc. Immunoglobulin variants for specific Fc epsilon receptors
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
NZ601815A (en) * 2008-03-31 2014-10-31 Genentech Inc Compositions and methods for treating and diagnosing asthma
US20180273626A1 (en) * 2015-09-11 2018-09-27 The Board Of Trustees Of The Leland Stanford Junio University Omalizumab resistant ige variants and their use in anti-ige therapy
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
EP4342541A3 (en) * 2017-04-07 2024-07-03 Kookmin University Industry Academy Cooperation Foundation Antibody fc variants for increased blood half-life
KR20220098056A (ko) * 2018-02-09 2022-07-08 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
EP3788078A4 (en) * 2018-05-04 2022-03-02 Allakos Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF CHRONIC URTICARIA

Also Published As

Publication number Publication date
US20230250191A1 (en) 2023-08-10
EP4180454A4 (en) 2024-10-02
KR20230042030A (ko) 2023-03-27
TWI896700B (zh) 2025-09-11
JP2026071342A (ja) 2026-04-28
CN116018352A (zh) 2023-04-25
WO2022007965A1 (zh) 2022-01-13
CA3185192A1 (en) 2022-01-13
EP4180454A9 (en) 2023-07-26
EP4180454A1 (en) 2023-05-17
AU2021306786A1 (en) 2023-02-16
BR112023000400A2 (pt) 2023-03-21
JP2023541217A (ja) 2023-09-29
TW202214703A (zh) 2022-04-16

Similar Documents

Publication Publication Date Title
CN112585165B (zh) 优化的抗tl1a抗体
TWI840399B (zh) 結合人il-4r的抗體、其抗原結合片段及其醫藥用途
CN107849136B (zh) 抗TfR抗体及其在治疗增殖性和炎性疾病中的用途
CN110669135B (zh) 一种双特异性抗体及其用途
KR20190134614A (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
JP7858629B2 (ja) Fgfr3抗体および使用の方法
JP2016179979A (ja) Pcsk9アンタゴニスト
WO2021170082A1 (zh) 抗cd47/抗pd-l1抗体及其应用
US20230138315A1 (en) Anti-angptl3 antibody and use thereof
US20230399394A1 (en) Antibody Binding to Human IL-33, Preparation Method Therefor, and Use Thereof
JP2026071342A (ja) 抗IgE改変抗体及びその適用
KR102709785B1 (ko) Il-5 항체, 이의 항원 결합 단편 및 이의 의학적 적용
IL297638A (en) Compounds and methods targeting interleukin-34
JP2026016483A (ja) 抗ヒトtlr7抗体
CN116368153A (zh) Zip12抗体
WO2022194201A1 (zh) 一种靶向cldn18.2的抗体或其抗原结合片段及其应用
CN118459583A (zh) 抗N3pGlu淀粉样蛋白β抗体及其用途
CN116284408A (zh) 结合人muc17的抗体、其制备方法及用途
WO2022037528A1 (zh) 结合bcma的单可变结构域及抗原结合分子
KR20250167608A (ko) 항-bdca2 항체
JP2024509369A (ja) 抗pd-l1抗体及びその使用
TWI918239B (zh) Gdf15中和抗體及其用途
JP2026513302A (ja) 抗il-25抗体及びその使用方法
HK40129973A (en) Antibody targeting tl1a and use thereof
WO2026017189A2 (zh) 抗il-31抗体、其药物组合物及用途